Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
about
Pharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsTargeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Molecular predictive markers in tumors of the gastrointestinal tractPhase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsAntiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerSingle cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.Synergistic interactions with PI3K inhibition that induce apoptosis.Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.Recurrent RAS and PIK3CA mutations in Erdheim-Chester diseaseSubsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerTargeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpressionSignificance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean InstitutionPresence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsSquamousness: Next-generation sequencing reveals shared molecular features across squamous tumor typesNext generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancerCyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemIn silico pathway analysis in cervical carcinoma reveals potential new targets for treatment.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.The Conundrum of Genetic "Drivers" in Benign Conditions.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.Molecular profiling of head and neck squamous cell carcinoma.Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
P2860
Q26766292-5EE8F89F-A12A-42DF-B75C-E49731E00881Q26775940-932872D2-9253-4172-A949-97706A0E512EQ28070583-ABD5CB9F-94D9-4BDC-B20A-810EC10FA3A2Q33422258-F1673D65-B7C5-42F4-8B83-F2691C55E688Q33435113-5F461019-DC40-4660-87A1-0BF215C34966Q33591658-976035E4-2CA6-4C08-8735-DC8E6CF8511FQ33756991-F4470812-7782-4F35-861F-784DBBAA2139Q33779691-FAFBA059-423D-4900-9375-08814759E954Q33806957-B45547C4-C141-4184-B763-574C3D68C72AQ33822197-3836D79B-E06E-4F86-900B-077850D41FD6Q33858387-6B9172D5-9142-4FCC-BF8A-A0601BB43DC3Q33940350-FB021435-BA40-49A8-A08C-A28CD4E62721Q34471821-527C8CCA-44EC-4BB1-97C3-91F846B99777Q34532980-51DAFC84-015E-4F62-8DCE-756470FBA153Q34619163-27FF31A0-9966-4745-9550-02E06AB04751Q34626967-99860DF9-192A-4E71-B691-349FC4F74E54Q34957243-30038E04-F005-4187-9D9F-69D436987D5FQ34995919-E6189BD8-266F-4175-8FB3-21E051E81BEAQ35606679-D83460BB-0ADF-44C0-8C89-D886CCF79F03Q35801713-19B4900E-1317-4645-B9C7-4F3FEAA87D6DQ35828697-00E2C65A-BAB5-44A0-A9B3-4C3B8CCAC2C2Q35849919-FAE281B9-F633-477F-B06D-EF3D1D11C62FQ35885555-1ED35F60-FA87-452A-85F7-AA2EE182105AQ35899928-AD2517B2-FB7D-4E4E-A5DB-D1699A1CEAE3Q35997083-2F5EBF61-616A-42B9-ABE5-64A1C1F76BB7Q36094586-4E20F79E-A854-4EBD-ACC0-8B604F35FFEFQ36184728-7436A4DA-6237-4CA3-BC24-84645BC056C5Q36188758-B0983413-C516-4A5F-80B5-071D0FEDCF4BQ36188947-AFBBC27E-3292-459B-B14A-FE2DDBF7DF3BQ36244592-54A96883-48D4-437A-9326-6DE68D1B11A5Q36260672-E325B503-D757-4ECD-9A6C-12CDC7AEA4F7Q36318871-A7BE909D-C5D8-4DF2-B4D0-9BAFFE4C422CQ36413639-93719BF4-8533-415D-81FF-BDD57A5050DFQ36771946-E54D2F49-9E47-4E7F-8C31-67D3340EB9CAQ37017110-FBC858F4-1484-4AD9-882A-9FE98BCCA0FCQ37220383-8A12BC03-CFF9-47B3-8AE8-3A779018F86FQ37245787-04D5CF02-9A8A-4D23-96C4-EFB091689488Q37268981-5151489F-C614-457C-881D-E4D0844CA96EQ37337359-2ACED103-2631-4A4E-9E6D-4E7C82A23FFCQ37536016-C1365F9E-AB05-43F1-9496-3E75CB08E590
P2860
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
@ast
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
@en
type
label
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
@ast
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
@en
prefLabel
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
@ast
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
@en
P2093
P2860
P50
P1433
P1476
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
@en
P2093
David S Hong
Gerald S Falchook
J Jack Lee
Jennifer J Wheler
Rajyalakshmi Luthra
Ralph G Zinner
Russell R Broaddus
Sarina A Piha-Paul
Stacy L Moulder
P2860
P304
P356
10.1016/J.CELREP.2013.12.035
P577
2014-01-16T00:00:00Z